Nancy A. Simonian's most recent trade in Syros Pharmaceuticals Inc. was a trade of 37,070 Common Stock done at an average price of $0.3 . Disclosure was reported to the exchange on Dec. 2, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Syros Pharmaceuticals Inc. | Simonian Nancy A. | Director | 02 Dec 2024 | 37,070 | 4,000 (0%) | 0% | 0.3 | 10,016 | Common Stock | |
| Syros Pharmaceuticals Inc. | Simonian A. Nancy | Director | 25 Nov 2024 | 134,713 | 41,070 (0%) | 0% | 0.3 | 35,739 | Common Stock | |
| Syros Pharmaceuticals Inc. | Nancy A. Simonian | Director | 31 Oct 2024 | 40,125 | 0 | - | - | Restricted Stock Units | ||
| Syros Pharmaceuticals Inc. | Nancy A. Simonian | Director | 31 Oct 2024 | 40,125 | 175,783 (0%) | 0% | - | Common Stock | ||
| Syros Pharmaceuticals Inc. | Nancy A. Simonian | Director | 05 Jun 2024 | 6,000 | 6,000 | - | - | Stock Option (right to buy) | ||
| Syros Pharmaceuticals Inc. | Nancy A. Simonian | Director | 05 Jun 2024 | 4,000 | 135,658 (0%) | 0% | 0 | Common Stock | ||
| Syros Pharmaceuticals Inc. | Nancy A. Simonian | Director | 31 Mar 2024 | 39,566 | 79,134 | - | - | Restricted Stock Units | ||
| Syros Pharmaceuticals Inc. | Nancy A. Simonian | Director | 31 Mar 2024 | 39,566 | 145,710 (0%) | 0% | - | Common Stock | ||
| Syros Pharmaceuticals Inc. | Nancy A. Simonian | Director | 31 Mar 2024 | 14,052 | 131,658 (0%) | 0% | 5.1 | 71,946 | Common Stock | |
| Syros Pharmaceuticals Inc. | Nancy A. Simonian | Director | 31 Mar 2024 | 6,000 | 106,144 (0%) | 0% | - | Common Stock | ||
| Syros Pharmaceuticals Inc. | Nancy A. Simonian | Director | 31 Mar 2024 | 6,000 | 12,000 | - | - | Restricted Stock Units | ||
| Syros Pharmaceuticals Inc. | A. Simonian Nancy | Director | 01 Dec 2023 | 30,399 | 0 | - | - | Stock Option (right to buy) | ||
| Syros Pharmaceuticals Inc. | Nancy Simonian A. | Director | 01 Dec 2023 | 29,399 | 0 | - | - | Stock Option (right to buy) | ||
| Syros Pharmaceuticals Inc. | A. Simonian Nancy | Director | 01 Dec 2023 | 28,001 | 0 | - | - | Stock Option (right to buy) | ||
| Syros Pharmaceuticals Inc. | Simonian A. Nancy | Director | 01 Dec 2023 | 17,499 | 0 | - | - | Stock Option (right to buy) | ||
| Syros Pharmaceuticals Inc. | Simonian Nancy A. | Director | 01 Dec 2023 | 7,500 | 0 | - | - | Stock Option (right to buy) | ||
| Seagen Inc | Nancy A. Simonian | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2023 | 2,044 | 64,797 (0%) | 0% | 0 | Common Stock | |
| Syros Pharmaceuticals Inc. | Nancy A. Simonian | Director, President & CEO | 31 Mar 2023 | 6,000 | 75,272 (0%) | 0% | - | Common Stock | ||
| Syros Pharmaceuticals Inc. | Nancy A. Simonian | Director, President & CEO | 31 Mar 2023 | 6,000 | 18,000 | - | - | Restricted Stock Units | ||
| Syros Pharmaceuticals Inc. | Nancy A. Simonian | Director, President & CEO | 31 Mar 2023 | 1,852 | 73,420 (0%) | 0% | 2.6 | 4,778 | Common Stock | |
| Syros Pharmaceuticals Inc. | Nancy A. Simonian | Director, President & CEO | 16 Feb 2023 | 118,700 | 118,700 | - | - | Restricted Stock Units | ||
| Seagen Inc | Nancy A. Simonian | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Dec 2022 | 8,750 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Seagen Inc | Nancy A. Simonian | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 36.70 per share. | 12 Dec 2022 | 8,750 | 62,753 (0%) | 0% | 36.7 | 321,125 | Common Stock |
| Syros Pharmaceuticals Inc. | Nancy A. Simonian | Director, President & CEO | 06 Oct 2022 | 115,000 | 115,000 | - | - | Stock Option (right to buy) | ||
| Syros Pharmaceuticals Inc. | Nancy A. Simonian | Director, President & CEO | 06 Oct 2022 | 80,250 | 80,250 | - | - | Restricted Stock Units | ||
| Seagen Inc | Nancy A. Simonian | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2022 | 3,676 | 3,676 | - | - | Non-Qualified Stock Option (right to buy) | |
| Seagen Inc | Nancy A. Simonian | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2022 | 1,503 | 54,003 (0%) | 0% | 0 | Common Stock | |
| Syros Pharmaceuticals Inc. | Nancy A. Simonian | Director, President & CEO | 01 Apr 2022 | 58,883 | 692,723 (1%) | 0% | 1.1 | 65,949 | Common Stock | |
| Seagen Inc | Nancy A. Simonian | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Mar 2022 | 25,000 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Seagen Inc | Nancy A. Simonian | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 20.04 per share. | 02 Mar 2022 | 25,000 | 52,500 (0%) | 0% | 20.0 | 501,000 | Common Stock |
| Syros Pharmaceuticals Inc. | Nancy A. Simonian | Director, President & CEO | 15 Feb 2022 | 400,000 | 400,000 | - | - | Restricted Stock Units | ||
| Syros Pharmaceuticals Inc. | Nancy A. Simonian | Director, President & CEO | 15 Feb 2022 | 375,000 | 375,000 | - | - | Stock Option (right to buy) | ||
| Syros Pharmaceuticals Inc. | Nancy A. Simonian | Director, President & CEO | 15 Feb 2022 | 240,000 | 240,000 | - | - | Restricted Stock Units | ||
| Seagen Inc | Nancy A. Simonian | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2021 | 3,462 | 3,462 | - | - | Non-Qualified Stock Option (right to buy) | |
| Seagen Inc | Nancy A. Simonian | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2021 | 1,402 | 27,500 (0%) | 0% | 0 | Common Stock | |
| Syros Pharmaceuticals Inc. | Nancy A. Simonian | Director, President & CEO | 17 Feb 2021 | 304,000 | 304,000 | - | - | Stock Option (right to buy) | ||
| Syros Pharmaceuticals Inc. | Nancy A. Simonian | Director, President & CEO | 18 Dec 2020 | 14,168 | 79,165 | - | - | Stock Option (right to buy) | ||
| Syros Pharmaceuticals Inc. | Nancy A. Simonian | Director, President & CEO | 18 Dec 2020 | 14,168 | 558,618 (1%) | 0% | 8.5 | 120,570 | Common Stock | |
| Syros Pharmaceuticals Inc. | Nancy A. Simonian | Director, President & CEO | 18 Dec 2020 | 10,761 | 544,450 (1%) | 0% | 3.0 | 32,713 | Common Stock | |
| Syros Pharmaceuticals Inc. | Nancy A. Simonian | Director, President & CEO | 18 Dec 2020 | 10,761 | 21,524 | - | - | Stock Option (right to buy) | ||
| Syros Pharmaceuticals Inc. | Nancy A. Simonian | Director, President & CEO | 18 Dec 2020 | 4,988 | 280,012 | - | - | Stock Option (right to buy) | ||
| Syros Pharmaceuticals Inc. | Nancy A. Simonian | Director, President & CEO | 18 Dec 2020 | 4,988 | 563,606 (1%) | 0% | 10.1 | 50,329 | Common Stock |